Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
P/E ratio for Revolution Medicines, Inc. (RVMD)
P/E ratio as of 2023: -7.44
According to Revolution Medicines, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -7.44. At the end of 2022 the company had a P/E ratio of -7.72.
P/E ratio history for Revolution Medicines, Inc. from 2017 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -7.44 |
| 2022 | -7.72 |
| 2021 | -10.19 |
| 2020 | -24.38 |
| 2019 | -35.77 |
| 2018 | -25.22 |
| 2017 | -33.86 |